Table 1.
Patient characteristics
| Characteristics | Reference cohort | COVID‐19 Cohort I | COVID‐19 Cohort II | Combined COVID‐19 Cohorts I + II |
|---|---|---|---|---|
| Patients (N) | 136 | 58 | 55 | 113 |
| Age (years) | 60 (49–69) | 67 (54–79) | 70 (57–79) | 69 (57–79) |
| <65 years | 87 (64.0%) | 26 (44.8%) | 20 (36.4%) | 46 (40.7%) |
| 65–80 years | 39 (28.7%) | 18 (31.0%) | 22 (40.0%) | 40 (38.4%) |
| >80 years | 10 (7.4%) | 14 (24.1) | 13 (23.6%) | 27 (23.9%) |
| Gender (male/female) | 76/60 (55.9%/44.1%) | 31/27 (53.4%/46.6%) | 38/17 (69.1%/30.9%) | 69/44 (69.1%/30.9%) |
| BMI (kg/m2) | 26.9 (23.6–30.3) | 27.2 (24.0–33.4) | 25.7 (22.9–27.8) | 26.1 (23.7–30.3) |
| BMI (>30 kg/m2) | 38 (27.9%) | 21 (36.2%) | 8 (14.5%) | 29 (25.7%) |
| Pre‐existing comorbidities | ||||
| Arterial hypertension | 50 (36.8%) | 34 (58.6%) | 39 (70.9%) | 73 (64.6%) |
| Cardiovascular disease | 37 (27.2%) | 20 (34.5%) | 34 (61.8%) | 54 (47.8%) |
| Diabetes mellitus | 29 (21.3%) | 13 (22.4%) | 25 (45.5%) | 38 (33.6%) |
| Chronic respiratory disease | 10 (7.4%) | 6 (10.3%) | 17 (30.9%) | 23 (20.4%) |
| Cerebrovascular disease | 12 (8.8%) | 14 (24.1%) | 14 (25.5%) | 28 (24.8%) |
| COVID‐19 severity | ||||
| Mild | NA | 28 (48.3%) | 16 (30.9%) | 44 (38.9%) |
| Complicated | NA | 17 (29.3%) | 19 (34.5%) | 36 (31.9%) |
| Critical | NA | 13 (22.4%) | 20 (34.5%) | 33 (29.2%) |
| Deceased | NR | 7 (12.1%) | 11 (20.0%) | 18 (15.9%) |
| Medical care | ||||
| Hospital care | 44 (32.4%) | 58 (100%) | 55 (100%) | 113 (100%) |
| Hospital care duration (days) | NR | 13 (8–21) | 19 (10–31) | 16 (8–25) |
| Intensive care | NR | 13 (22.8%) | 16 (29.1%) | 29 (25.9%) |
| Intensive care duration (days) | NR | 25 (8–37) | 17 (9–39) | 20 (9–38) |
| Invasive ventilation | NR | 12 (21.1%) | 11 (20%) | 23 (20.5%) |
| Invasive ventilation duration (days) | NR | 15 (5–35) | 22 (7–38) | 18 (6–35) |
| Vasopressor therapy | NR | 8 (14.3%) | 10 (18.2%) | 18 (16.2%) |
| Renal replacement therapy | NR | 3 (5.2%) | 6 (10.9%) | 9 (8.9%) |
| ECMO therapy | NR | 1 (1.8%) | 2 (3.6%) | 3 (2.7%) |
| Dexamethasone therapy | NR | 22 (37.9%) | 31 (56.4%) | 53 (46.9%) |
| Anticoagulation | ||||
| None | NR | 3 (5.2%) | 4 (7.3%) | 7 (6.3%) |
| Prophylactic LMWH | NR | 39 (68.4%) | 30 (54.5%) | 69 (61.6%) |
| Therapeutic LMWH | NR | 15 (26.3%) | 21 (38.1%) | 36 (32.1%) |
| Oral anticoagulation | NR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
BMI, body mass index; LMWH, low molecular weight heparin, ECMO, extracorporeal membrane oxygenation, NA not applicable, NR, not rated. Patient characteristics presented as median (interquartile range) or number (%).